ABVC American BriVision (Holding) Corporation

American BriVision (Holding) Corp. is a clinical stage biopharmaceutical company, which focuses on the development of new drugs and medical devices. The company also integrates research achievements from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. It conducts clinical trials of translational medicine for Proof of Concept and out-licenses it to international pharmaceutical companies. Its products include BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia. The company was founded in 1990 and is headquartered in Fremont, CA.

$0.71  -0.01 (-1.10%)
As of 02/07/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/15/2013
Outstanding shares:  32,632,329
Average volume:  190,440
Market cap:   $22,943,791
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%